Mineralys Therapeutics, Inc. ( MLYS) Bank of America Global Healthcare Conference 2026 May 12, 2026 12:20 PM EDT From Mineralys, I have here with me today, Jon Congleton. Jon, thanks for joining us. I ...
Historically, Monogram Health’s flagship area of expertise was based on kidney health. But the polychronic nature of this patient population has made it clear that healthcare professionals cannot ...
A new experimental drug lowered blood pressure and sharply reduced signs of kidney damage in people with chronic kidney ...
A Canadian study has raised new questions about whether some commonly prescribed blood pressure medications could be linked ...
High blood pressure can be managed with several medication classes, each with unique benefits, side effects, and costs. From ARBs and ACE inhibitors to beta blockers and calcium channel blockers, the ...
Medically reviewed by Jeffrey S. Lander, MD Key Takeaways Combining blood pressure medications, such as a long-acting calcium channel blocker with an ACE inhibitor or ARB, is often more effective than ...
The IgAN market is growing due to rising prevalence, improved diagnostics, novel immunotherapies, ongoing clinical trials of therapies such as Zigakibart (Novartis), Sefaxersen (F. Hoffmann-La ...
Officials have warned of a serious shortage of a common blood pressure medicine across the UK. A “serious shortage protocol” notice has been issued for ramipril 1.25mg capsule ...
Both ACE inhibitors and ARBs reduce blood pressure and are recommended first-line in current guidelines, but whether either class confers superior long-term protection against death or major ...
Median survival following diagnosis of idiopathic pulmonary fibrosis (IPF) is typically three to five years, despite the availability of antifibrotic agents, such as Ofev (nintedanib) and Esbriet ...
Angiotensin-converting enzyme (ACE) inhibitors are widely prescribed antihypertensives with established cardioprotective effects. Prior mechanistic and clinical work has raised the possibility that ...